



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 860 430 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
12.06.2002 Bulletin 2002/24

(51) Int Cl.7: **C07C 405/00, A61K 31/557**

(21) Application number: **98300769.1**

(22) Date of filing: **03.02.1998**

(54) **Omega-cycloalkyl-prostaglandin E2 derivatives**

Omega-Zykloalkyl-Prostaglandin E2 Derivate

Dérivés omega-cycloalkyl-prostaglandine E2

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE**

(30) Priority: **04.02.1997 JP 3549997
06.11.1997 JP 31916997**

(43) Date of publication of application:
26.08.1998 Bulletin 1998/35

(73) Proprietor: **ONO PHARMACEUTICAL CO., LTD.
Chuo-ku Osaka 541 (JP)**

(72) Inventors:
• **Tani, Kousuke, c/o Minase Research Inst.
Mishima-gun, Osaka (JP)**

• **Ohuchida, Shuichi, c/o Minase Research Inst.
Mishima-gun, Osaka (JP)**

(74) Representative: **Bentham, Stephen et al
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5JJ (GB)**

(56) References cited:
**US-A- 4 132 738 US-A- 4 336 404
US-A- 4 363 817**

EP 0 860 430 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).